Aptose Biosciences Files 8-K Report
Ticker: APTOF · Form: 8-K · Filed: Jan 13, 2025 · CIK: 882361
| Field | Detail |
|---|---|
| Company | Aptose Biosciences INC. (APTOF) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
Related Tickers: APTO
TL;DR
APTO filed an 8-K, mostly exhibits. Keep an eye out for details.
AI Summary
On January 13, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disclosures related to the company's financial status and operations. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This 8-K filing signals that Aptose Biosciences Inc. is providing updated information to the SEC, which could include important financial disclosures or exhibit filings relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, with no immediate indication of significant negative or positive events.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- 66 Wellington Street West, Suite 5300 (address) — Business and Mail Address
FAQ
What is the primary purpose of this 8-K filing by Aptose Biosciences Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is January 13, 2025.
What is the Commission File Number for Aptose Biosciences Inc.?
The Commission File Number for Aptose Biosciences Inc. is 001-32001.
What is the business and mailing address of Aptose Biosciences Inc.?
The business and mailing address of Aptose Biosciences Inc. is 66 Wellington Street West, Suite 5300, Toronto, A6, M5K 1E6.
What was Aptose Biosciences Inc. formerly known as?
Aptose Biosciences Inc. was formerly known as LORUS THERAPEUTICS INC. and IMUTEC PHARMA INC.
Filing Stats: 381 words · 2 min read · ~1 pages · Grade level 10.1 · Accepted 2025-01-13 08:01:15
Filing Documents
- f8k_011325.htm (8-K) — 19KB
- exh_991.htm (EX-99.1) — 33KB
- exh991_01.jpg (GRAPHIC) — 63KB
- exh991_02.jpg (GRAPHIC) — 132KB
- exh991_03.jpg (GRAPHIC) — 109KB
- exh991_04.jpg (GRAPHIC) — 129KB
- exh991_05.jpg (GRAPHIC) — 174KB
- exh991_06.jpg (GRAPHIC) — 196KB
- exh991_07.jpg (GRAPHIC) — 187KB
- exh991_08.jpg (GRAPHIC) — 126KB
- exh991_09.jpg (GRAPHIC) — 119KB
- exh991_10.jpg (GRAPHIC) — 125KB
- exh991_11.jpg (GRAPHIC) — 122KB
- exh991_12.jpg (GRAPHIC) — 136KB
- exh991_13.jpg (GRAPHIC) — 136KB
- exh991_14.jpg (GRAPHIC) — 131KB
- exh991_15.jpg (GRAPHIC) — 128KB
- exh991_16.jpg (GRAPHIC) — 116KB
- exh991_17.jpg (GRAPHIC) — 108KB
- exh991_18.jpg (GRAPHIC) — 141KB
- exh991_19.jpg (GRAPHIC) — 163KB
- exh991_20.jpg (GRAPHIC) — 34KB
- 0001171843-25-000194.txt ( ) — 3781KB
- apto-20250113.xsd (EX-101.SCH) — 3KB
- apto-20250113_lab.xml (EX-101.LAB) — 33KB
- apto-20250113_pre.xml (EX-101.PRE) — 22KB
- f8k_011325_htm.xml (XML) — 4KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. 99.1 Aptose Corporate Presentation - January 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: January 13, 2025 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. President and Chief Executive Officer